 Biocept Inc NASDAQ:BIOC and Plus Therapeutics Inc have announced a comprehensive laboratory services agreement for Plus Therapeutics ReSPECT-LM trial for the treatment of cancer in the membranes that surround the brain and spinal cord. Under the multi-year agreement, Biocepts cerebrospinal fluid CSF assay CNSide1 will be employed in Plus Therapeutics ReSPECT-LM Phase 12a dose-escalation clinical trial of Rhenium-186 NanoLiposome 186RNL for the treatment of patients with leptomeningeal metastases LM. 